158 related articles for article (PubMed ID: 32316877)
21. Experience with ambulatory high-dose methotrexate administration as CNS prophylaxis in patients with non-Hodgkin lymphoma.
Pampín R; Labeaga Y; Rodríguez B; Fernández B; Fernández R; Carbajales M
J Oncol Pharm Pract; 2020 Apr; 26(3):549-555. PubMed ID: 31156052
[TBL] [Abstract][Full Text] [Related]
22. Preventing and Managing Toxicities of High-Dose Methotrexate.
Howard SC; McCormick J; Pui CH; Buddington RK; Harvey RD
Oncologist; 2016 Dec; 21(12):1471-1482. PubMed ID: 27496039
[TBL] [Abstract][Full Text] [Related]
23. Effect of Levetiracetam on Time to High-Dose Methotrexate Clearance in Patients With Hematologic Malignancies.
Lou U; Kwok J; Nguyen TA; Zhou A; Luk SO
J Clin Pharmacol; 2020 Mar; 60(3):324-330. PubMed ID: 31729053
[TBL] [Abstract][Full Text] [Related]
24. pH and salivary sodium bicarbonate during the administration protocol for methotrexate in children with leukemia.
Rojas de Morales T; Navas R; Viera N; Alvarez CJ; Chaparro N; Griman D
Med Oral Patol Oral Cir Bucal; 2007 Oct; 12(6):E435-9. PubMed ID: 17909509
[TBL] [Abstract][Full Text] [Related]
25. Risk factors associated with delayed methotrexate clearance and increased toxicity in pediatric patients with osteosarcoma.
Young EP; Cheng WS; Bernhardt MB; Wang LL; Rainusso N; Foster JH
Pediatr Blood Cancer; 2020 Apr; 67(4):e28123. PubMed ID: 31867853
[TBL] [Abstract][Full Text] [Related]
26. What can clinicians learn from therapeutic studies about the treatment of acute oral methotrexate poisoning?
Chan BS; Dawson AH; Buckley NA
Clin Toxicol (Phila); 2017 Feb; 55(2):88-96. PubMed ID: 28084171
[TBL] [Abstract][Full Text] [Related]
27. High-dose methotrexate in children with acute lymphoblastic leukemia: 7-hydroxymethotrexate systemic exposure and urinary concentrations at the steady state correlate well with those of methotrexate.
Chládková J; Hak J; Martínková J; Chládek J
Arzneimittelforschung; 2010; 60(12):769-75. PubMed ID: 21265469
[TBL] [Abstract][Full Text] [Related]
28. Delayed elimination of high-dose methotrexate and use of carboxypeptidase G2 in pediatric patients during treatment for acute lymphoblastic leukemia.
Svahn T; Mellgren K; Harila-Saari A; Åsberg A; Kanerva J; Jónsson Ó; Vaitkeviciene G; Stamm Mikkelssen T; Schmiegelow K; Heldrup J
Pediatr Blood Cancer; 2017 Jul; 64(7):. PubMed ID: 27966809
[TBL] [Abstract][Full Text] [Related]
29. Ambulatory High-dose Methotrexate Administration in Pediatric Osteosarcoma Patients at a Single Institution in Argentina.
Villegas Rubio JA; Cacciavillano W; Rose A; Zubizarreta P; Scopinaro M
J Pediatr Hematol Oncol; 2017 Oct; 39(7):e349-e352. PubMed ID: 28937522
[TBL] [Abstract][Full Text] [Related]
30. [Study on elimination delay in high dose methotrexate therapy in childhood acute lymphoblastic leukemia].
Xu WQ; Tang YM; Fang CQ; Song H; Shi SW; Yang SL; Ren DT; Shen HQ; Qian BQ
Zhonghua Xue Ye Xue Za Zhi; 2005 Jan; 26(1):15-8. PubMed ID: 15946502
[TBL] [Abstract][Full Text] [Related]
31. Relationship between oral mucositis and high-dose methotrexate therapy in pediatric acute lymphoblastic leukemia.
Maiguma T; Hayashi Y; Ueshima S; Kaji H; Egawa T; Chayama K; Morishima T; Kitamura Y; Sendo T; Gomita Y; Teshima D
Int J Clin Pharmacol Ther; 2008 Nov; 46(11):584-90. PubMed ID: 19000557
[TBL] [Abstract][Full Text] [Related]
32. High-dose methotrexate therapy of childhood acute lymphoblastic leukemia: lack of relation between serum methotrexate concentration and creatinine clearance.
Joannon P; Oviedo I; Campbell M; Tordecilla J
Pediatr Blood Cancer; 2004 Jul; 43(1):17-22. PubMed ID: 15170885
[TBL] [Abstract][Full Text] [Related]
33. Standardized Supportive Care Documentation Improves Safety of High-Dose Methotrexate Treatment.
Alsdorf WH; Karagiannis P; Langebrake C; Bokemeyer C; Frenzel C
Oncologist; 2021 Feb; 26(2):e327-e332. PubMed ID: 33215763
[TBL] [Abstract][Full Text] [Related]
34. Oral acetazolamide in the assessment of (urine-blood) PCO2.
Alon U; Hellerstein S; Warady BA
Pediatr Nephrol; 1991 May; 5(3):307-11. PubMed ID: 1651097
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of incidence and risk factors for high-dose methotrexate-induced nephrotoxicity.
Wiczer T; Dotson E; Tuten A; Phillips G; Maddocks K
J Oncol Pharm Pract; 2016 Jun; 22(3):430-6. PubMed ID: 26152702
[TBL] [Abstract][Full Text] [Related]
36. The impact of prehydration on the clearance and toxicity of high-dose methotrexate for pediatric patients.
Karremann M; Sauerbier J; Meier C; Vetter C; Schneider H; Buchholz B; Mildenberger S; Dürken M
Leuk Lymphoma; 2014 Dec; 55(12):2874-8. PubMed ID: 24576168
[TBL] [Abstract][Full Text] [Related]
37. Improving the safety of high-dose methotrexate for children with hematologic cancers in settings without access to MTX levels using extended hydration and additional leucovorin.
Vaishnavi K; Bansal D; Trehan A; Jain R; Attri SV
Pediatr Blood Cancer; 2018 Dec; 65(12):e27241. PubMed ID: 29768710
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of a pediatric pre-chemotherapy rapid hydration protocol: A quality assurance project.
McKinnon K; Tran T; Lewis V
J Oncol Pharm Pract; 2023 Apr; 29(3):679-684. PubMed ID: 35156868
[TBL] [Abstract][Full Text] [Related]
39. Safety and efficacy of high-dose methotrexate for osteosarcoma in adolescents compared with young adults.
Wippel B; Gundle KR; Dang T; Paxton J; Bubalo J; Stork L; Fu R; Ryan CW; Davis LE
Cancer Med; 2019 Jan; 8(1):111-116. PubMed ID: 30580500
[TBL] [Abstract][Full Text] [Related]
40. Glucarpidase for the treatment of life-threatening methotrexate overdose.
Tuffaha HW; Al Omar S
Drugs Today (Barc); 2012 Nov; 48(11):705-11. PubMed ID: 23170306
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
